Palafox-Romo R, Malagón-Liceaga A, Méndez-Flores S

Idioma: Español
Referencias bibliográficas: 20
Paginas: 176-181
Archivo PDF: 126.17 Kb.

RESUMEN

En este artículo se revisa la relevancia de los efectos adversos cutáneos asociados a la inmunoterapia mediante inhibidores de puntos de control inmunológico (ICI), como los que van contra la proteína de muerte celular programada-1 (PD-1), el ligando de muerte celular programada-1 (PD-l1) y el antígeno 4 de linfocitos t citotóxicos (CTLA-4), que han transformado el abordaje terapéutico del cáncer. Aunque estos ICI potencian respuestas inmunológicas contra células malignas, también pueden inducir afecciones cutáneas, desde exantemas hasta el síndrome similar a Stevens-Johnson. La incidencia varía según el tipo de ICI y el cáncer tratado. Se destaca la necesidad de gestionar rigurosamente estos efectos adversos proponiendo pautas según su gravedad, y se enfatiza la colaboración entre oncólogos y dermatólogos.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Sakurai K, Niitsuma S, Iizuka A et al., Immune-related adverseevents in various organs caused by immune checkpoint inhibitors,Allergol Int 2022; 71(2):169-78.

2. Li B, Chan HL y Chen P, Immune checkpoint inhibitors: basicsand challenges, Curr Med Chem 2019; 26(17): 3009-25.

3. Carlino MS, Larkin J y Long GV, Immune checkpoint inhibitors inmelanoma, Lancet 2021; 398(10304):1002-14.

4. Wang J, Yang T y Xu J, Therapeutic development of immunecheckpoint inhibitors, Adv Exp Med Biol 2020; 1248:619-49.

5. Ellis SR, Vierra AT, Millsop JW, Lacouture ME y Kiuru M, Dermatologictoxicities to immune checkpoint inhibitor therapy: areview of histopathologic features, J Am Acad Dermatol 2020;83(4):1130-43.

6. Sibaud V, Dermatologic reactions to immune checkpoint inhibitors:skin toxicities and immunotherapy, Am J Clin Dermatol2018; 19(3):345-61.

7. El Osta B, Hu F, Sadek R, Chintalapally R y Tang SC, Not allimmune-checkpoint inhibitors are created equal: meta-analysisand systematic review of immune-related adverse events incancer trials, Crit Rev Oncol Hematol 2017; 119:1-12.

8. Khoja L, Day D, Wei-Wu CT, Siu LL y Hansen AR, Tumour andclass-specific patterns of immune-related adverse events ofimmune checkpoint inhibitors: a systematic review, Ann Oncol2017; 28(10):2377-85.

9. Postow MA, Sidlow R y Hellmann MD, Immune-related adverseevents associated with immune checkpoint blockade, N Engl JMed 2018; 378(2):158-68.

10. Muntyanu A, Netchiporouk E, Gerstein W, Gniadecki R y LitvinovIV, Cutaneous immune-related adverse events (iraes) toimmune checkpoint inhibitors: a dermatology perspective onmanagement, J Cutan Med Surg 2021; 25(1):59-76.

11. Watanabe T y Yamaguchi Y, Cutaneous manifestations associatedwith immune checkpoint inhibitors, Front Immunol 2023;14:1071983.

12. Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J y Delord JP,Dermatologic complications of anti-pd-1/pd-l1 immune checkpointantibodies, Curr Opin Oncol. 2016; 28(4):254-63.

13. Shi VJ, Rodic N, Gettinger S, Leventhal JS, Neckman JP, GirardiM et al., Clinical and histologic features of lichenoid mucocutaneouseruptions due to anti-programmed cell death 1 and antiprogrammed cell death ligand 1 immunotherapy, jama Dermatol2016; 152(10):1128-36.

14. Goldinger SM, Stieger P, Meier B, Micaletto S, Contassot E,French LE et al., Cytotoxic cutaneous adverse drug reactionsduring anti- pd-1 therapy, Clin Cancer Res 2016; 22(16):4023-9.

15. Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G yWeber JS, Nivolumab in resected and unresectable metastaticmelanoma: characteristics of immune-related adverseevents and association with outcomes, Clin Cancer Res 2016;22(4):886-94.

16. Zarbo A, Belum VR, Sibaud V, Oudard S, Postow MA, Hsieh JJet al., Immune-related alopecia (areata and universalis) in cancerpatients receiving immune checkpoint inhibitors, Br J Dermatol2017; 176(6):1649-52.

17. Siegel J, Totonchy M, Damsky W, Berk-Krauss J, Castiglione FJr, Sznol M et al., Bullous disorders associated with anti-pd-1and anti-pd-l1 therapy: a retrospective analysis evaluating theclinical and histopathologic features, frequency, and impact oncancer therapy, J Am Acad Dermatol. 2018; 79(6):1081-8.

18. Shi CR, Shaughnessy M, Sehgal K, Clark JR, Reynolds KL, ToyoharaJ et al., Successful rechallenge with pembrolizumab aftercase of progressive immunotherapy-related mucocutaneouseruption (pirme), a Stevens-Johnson syndrome-like reaction, IntJ Dermatol 2023; 62(10):1292-4.

19. Maloney NJ, Ravi V, Cheng K, Bach DQ y Worswick S, Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactionsto checkpoint inhibitors: a systematic review, Int J Dermatol 2020; 59(6):e183-8.

20. Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, AdkinsS, Anadkat M et al., Management of immune-related adverseevents in patients treated with immune checkpoint inhibitor therapy:asco guideline update, J Clin Oncol 2021; 39(36):4073-126.